JP2010519289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519289A5 JP2010519289A5 JP2009550773A JP2009550773A JP2010519289A5 JP 2010519289 A5 JP2010519289 A5 JP 2010519289A5 JP 2009550773 A JP2009550773 A JP 2009550773A JP 2009550773 A JP2009550773 A JP 2009550773A JP 2010519289 A5 JP2010519289 A5 JP 2010519289A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- independently
- group
- metalloprotein
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000010750 Metalloproteins Human genes 0.000 claims 4
- 108010063312 Metalloproteins Proteins 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90285407P | 2007-02-23 | 2007-02-23 | |
| US60/902,854 | 2007-02-23 | ||
| PCT/IL2008/000230 WO2008102359A1 (en) | 2007-02-23 | 2008-02-21 | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013150040A Division JP5792231B2 (ja) | 2007-02-23 | 2013-07-19 | 金属タンパク質の活性を阻害するために有用な抗体および該抗体を含有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010519289A JP2010519289A (ja) | 2010-06-03 |
| JP2010519289A5 true JP2010519289A5 (enExample) | 2011-01-20 |
| JP5513130B2 JP5513130B2 (ja) | 2014-06-04 |
Family
ID=39534848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550773A Expired - Fee Related JP5513130B2 (ja) | 2007-02-23 | 2008-02-21 | 金属タンパク質の活性を阻害するために有用な抗体および該抗体を含有する医薬組成物 |
| JP2013150040A Expired - Fee Related JP5792231B2 (ja) | 2007-02-23 | 2013-07-19 | 金属タンパク質の活性を阻害するために有用な抗体および該抗体を含有する医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013150040A Expired - Fee Related JP5792231B2 (ja) | 2007-02-23 | 2013-07-19 | 金属タンパク質の活性を阻害するために有用な抗体および該抗体を含有する医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US8324355B2 (enExample) |
| EP (1) | EP2155691B1 (enExample) |
| JP (2) | JP5513130B2 (enExample) |
| KR (1) | KR20090113908A (enExample) |
| CN (1) | CN101702906B (enExample) |
| BR (1) | BRPI0807256A2 (enExample) |
| CA (1) | CA2678304A1 (enExample) |
| IL (2) | IL224120A (enExample) |
| MX (1) | MX2009008914A (enExample) |
| RU (1) | RU2503682C2 (enExample) |
| WO (1) | WO2008102359A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101702906B (zh) | 2007-02-23 | 2014-02-12 | 耶达研究及发展有限公司 | 用于抑制金属蛋白活性的抗体和含有所述抗体的药物组合物 |
| EP2231186A4 (en) | 2007-12-17 | 2012-08-08 | Dyax Corp | COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS |
| AU2009221916A1 (en) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| EP2403964B1 (en) * | 2009-03-02 | 2021-09-08 | Massachusetts Institute of Technology | Methods and products for in vivo enzyme profiling |
| WO2011092700A1 (en) | 2010-01-27 | 2011-08-04 | Yeda Research And Development Co. Ltd. | Antibodies that inhibit metalloproteins |
| SI2608809T1 (sl) | 2010-08-27 | 2019-08-30 | Gilead Biologics, Inc. | Protitelesa proti matriksu metaloproteinaze 9 |
| ES2688457T3 (es) | 2010-10-28 | 2018-11-02 | Yeda Research And Development Co. Ltd. | Métodos de generación de anticuerpos contra metaloenzimas |
| US10314909B2 (en) | 2011-10-21 | 2019-06-11 | Dyax Corp. | Combination therapy comprising an MMP-14 binding protein |
| BR112014021081A2 (pt) | 2012-02-29 | 2017-07-04 | Gilead Biologics Inc | anticorpos para a metaloproteinase da matriz 9 |
| WO2014197840A1 (en) | 2013-06-07 | 2014-12-11 | Massachusetts Institute Of Technology | Affinity-based detection of ligand-encoded synthetic biomarkers |
| RU2729546C2 (ru) | 2014-04-03 | 2020-08-07 | Цсл Беринг Аг | Распыление иммуноглобулина |
| US11019620B2 (en) | 2014-05-19 | 2021-05-25 | Qualcomm Incorporated | Apparatus and method for inter-band pairing of carriers for time division duplex transmit- and receive-switching and its application to multiplexing of different transmission time intervals |
| US11452121B2 (en) * | 2014-05-19 | 2022-09-20 | Qualcomm Incorporated | Apparatus and method for synchronous multiplexing and multiple access for different latency targets utilizing thin control |
| EP2985296A1 (en) * | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Antibodies specific for MMP9 |
| US10305637B2 (en) * | 2016-04-04 | 2019-05-28 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting and receiving feedback in wireless communication system |
| EP3634459A4 (en) * | 2017-02-10 | 2021-01-06 | Washington University | ANTIBODIES DIRECTED AGAINST TIP1 AND THEIR PROCEDURES FOR USE |
| AU2018248327B2 (en) | 2017-04-07 | 2024-10-10 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| US11926655B2 (en) | 2017-07-18 | 2024-03-12 | Daiichi Sankyo Company, Limited | Active MMP9-binding peptide |
| WO2020068920A2 (en) | 2018-09-25 | 2020-04-02 | Massachusetts Institute Of Technology | Lung protease nanosensors and uses thereof |
| WO2020150560A1 (en) | 2019-01-17 | 2020-07-23 | Massachusetts Institute Of Technology | Sensors for detecting and imaging of cancer metastasis |
| IL264768A (en) | 2019-02-10 | 2020-08-31 | Sagi Irit | Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof |
| US11332546B2 (en) | 2019-05-21 | 2022-05-17 | The Regents Of The University Of California | Protease inhibitory antibodies and methods of use thereof |
| CA3212755A1 (en) * | 2021-04-05 | 2022-10-13 | Thomas J. Montine | Enantiomer selective action on neurotransmission |
| WO2025075789A1 (en) * | 2023-10-03 | 2025-04-10 | Merck Sharp & Dohme Llc | Immunoassay for detecting tau phosphorylated at serine 413 |
| AU2024356800A1 (en) | 2023-10-05 | 2026-04-02 | Ashibio, Inc. | Methods and compositions for treating mmp-9 mediated disorders |
| WO2026076260A1 (en) | 2024-10-03 | 2026-04-09 | Ashibio, Inc. | Methods and compositions for mmp-9 inhibition for use with non-genetic heterotopic ossification disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595700A (en) | 1984-12-21 | 1986-06-17 | G. D. Searle & Co. | Thiol based collagenase inhibitors |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| JP3348725B2 (ja) | 1992-04-07 | 2002-11-20 | ブリティッシュ バイオテック ファーマシューティカルズ リミテッド | ヒドロキサム酸ベースのコラゲナーゼとサイトカイン阻害剤 |
| GB9320660D0 (en) | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
| AU2361295A (en) | 1994-04-28 | 1995-11-29 | Merck & Co., Inc. | N-carboxyalkyl derivatives as antidegenerative active agents |
| WO1995029892A1 (en) | 1994-04-28 | 1995-11-09 | The Du Pont Merck Pharmaceutical Company | Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents |
| GB9416897D0 (en) | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
| EP0757984B1 (en) | 1995-08-08 | 2002-10-30 | Ono Pharmaceutical Co., Ltd. | Hydroxamic acid derivatives useful for inhibiting gelatinase |
| IL116126A0 (en) * | 1995-11-24 | 1996-01-31 | Yeda Res & Dev | Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| WO1997024117A1 (en) | 1996-01-02 | 1997-07-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds |
| WO1997049679A1 (en) | 1996-06-27 | 1997-12-31 | Ono Pharmaceutical Co., Ltd. | Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient |
| US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| NZ509439A (en) | 1998-07-30 | 2002-10-25 | Warner Lambert Co | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| IL132105A0 (en) * | 1998-12-24 | 2001-03-19 | Yeda Res & Dev | Caspase-8 interacting proteins |
| ES2369498T3 (es) * | 2003-04-04 | 2011-12-01 | Yeda Research And Development Co., Ltd. | Anticuerpos para inhibir la actividad de mmp-2 y mmp-9. |
| CN101702906B (zh) | 2007-02-23 | 2014-02-12 | 耶达研究及发展有限公司 | 用于抑制金属蛋白活性的抗体和含有所述抗体的药物组合物 |
| WO2011092700A1 (en) | 2010-01-27 | 2011-08-04 | Yeda Research And Development Co. Ltd. | Antibodies that inhibit metalloproteins |
-
2008
- 2008-02-21 CN CN200880012673.1A patent/CN101702906B/zh not_active Expired - Fee Related
- 2008-02-21 WO PCT/IL2008/000230 patent/WO2008102359A1/en not_active Ceased
- 2008-02-21 MX MX2009008914A patent/MX2009008914A/es not_active Application Discontinuation
- 2008-02-21 JP JP2009550773A patent/JP5513130B2/ja not_active Expired - Fee Related
- 2008-02-21 US US12/449,728 patent/US8324355B2/en active Active
- 2008-02-21 BR BRPI0807256-6A2A patent/BRPI0807256A2/pt not_active IP Right Cessation
- 2008-02-21 CA CA002678304A patent/CA2678304A1/en not_active Abandoned
- 2008-02-21 RU RU2009132006/04A patent/RU2503682C2/ru not_active IP Right Cessation
- 2008-02-21 KR KR1020097019866A patent/KR20090113908A/ko not_active Ceased
- 2008-02-21 EP EP08710230.7A patent/EP2155691B1/en not_active Not-in-force
-
2012
- 2012-08-28 US US13/596,090 patent/US8486653B2/en active Active
-
2013
- 2013-01-06 IL IL224120A patent/IL224120A/en active IP Right Grant
- 2013-01-06 IL IL224121A patent/IL224121A/en active IP Right Grant
- 2013-04-29 US US13/872,265 patent/US9416195B2/en not_active Expired - Fee Related
- 2013-07-19 JP JP2013150040A patent/JP5792231B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-23 US US15/161,375 patent/US9902783B2/en active Active
-
2018
- 2018-01-09 US US15/865,479 patent/US20180134808A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009132006A (ru) | Антитела и содержащие их фармацевтические композиции, подходящие для ингибирования активности металлопротеинов | |
| JP2008500025A5 (enExample) | ||
| RU2015112025A (ru) | Новое соединение с эффектами тромболизиса, акцептирования свободных радикалов и направленного действия на тромб, а также способ его получения и применение | |
| RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
| RU2011122487A (ru) | Новые аналоги сс-1065 и их конъюгаты | |
| RU2016101244A (ru) | Новые конъюгаты аналогов сс-1065 и бифункциональные линкеры | |
| CA2653941A1 (en) | Substituted amino purine derivatives and uses thereof | |
| JP2012504632A5 (enExample) | ||
| JP2021524270A5 (enExample) | ||
| CA2441410A1 (en) | Compounds and method of treatment having agonist-like activity selective at alpha 2b or 2b/2c adrenergic receptors | |
| JP2012523457A5 (enExample) | ||
| JP2007504161A5 (enExample) | ||
| JP2013521279A5 (enExample) | ||
| JP2008525033A5 (enExample) | ||
| JP2010523717A5 (enExample) | ||
| JP2010511388A5 (enExample) | ||
| JP2013512915A5 (enExample) | ||
| AR058419A1 (es) | Compuestos de nucleosidos triciclicos para tratar infecciones virales | |
| RU2016130933A (ru) | Сульфонамид-содержащие связывающие системы для лекарственных конъюгатов | |
| EA201591353A1 (ru) | Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента | |
| JP2013507423A5 (enExample) | ||
| JP2009538336A5 (enExample) | ||
| JP2017533886A5 (enExample) | ||
| JP2011506274A5 (enExample) | ||
| JP2012505657A5 (enExample) |